Literature DB >> 28633967

The effects of chronic FAAH inhibition on myocardial lipid metabolism in normotensive and DOCA-salt hypertensive rats.

Agnieszka Polak1, Ewa Harasim-Symbor2, Barbara Malinowska3, Irena Kasacka4, Anna Pędzińska-Betiuk3, Jolanta Weresa3, Adrian Chabowski1.   

Abstract

AIMS: There is significant evidence that the endocannabinoid system (ECS) takes part in the regulation of the cardiovascular system in hypertension. It is quite well established that hypertension causes several changes in the heart metabolism, but it is still unknown whether the ECS affects this process. Therefore, we investigated the influence of prolonged ECS activation on myocardial lipid metabolism in deoxycorticosterone acetate (DOCA)-salt hypertensive rats by chronic fatty acid amide hydrolase (FAAH) inhibition.
MATERIALS AND METHODS: We examined the uptake and oxidation of palmitic acid during the heart perfusion as well as intramyocardial and plasma lipid contents using gas liquid chromatography. Total, plasmalemmal and intracellular expressions of selected proteins were estimated by the Western blot technique. Moreover, the left ventricle's morphology, including myocardial vessels density, was measured using immunohistochemistry. KEY
FINDINGS: We demonstrated that hypertension induced cardiomyocytes and myocardial blood vessels hypertrophy, followed by a reduction in myocardial palmitate oxidation. Interestingly, prolonged activation of the ECS in the normotensive rats induced cardiomyocyte enlargement and intensified fatty acids metabolism. We have also shown that FAAH inhibition improved morphology of coronary blood vessels and only partially maintained its effect on lipid metabolism in the DOCA-salt hearts (i.e. elevated plasma and intramyocardial TAG contents as well as plasmalemmal FAT/CD36 and total FATP1 expressions). SIGNIFICANCE: This study revealed that chronic FAAH inhibition has no protective effects on the heart lipid metabolism in hypertension.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DOCA; Endocannabinoids; Fat/CD36; Fatty acid transport; Hypertension; URB597

Mesh:

Substances:

Year:  2017        PMID: 28633967     DOI: 10.1016/j.lfs.2017.06.019

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

Review 1.  Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.

Authors:  Virna Margarita Martín Giménez; Sandra Edith Noriega; Diego Enrique Kassuha; Lucía Beatriz Fuentes; Walter Manucha
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-16

2.  Experimental Activation of Endocannabinoid System Reveals Antilipotoxic Effects on Cardiac Myocytes.

Authors:  Ewa Harasim-Symbor; Agnieszka Polak-Iwaniuk; Karolina Konstantynowicz-Nowicka; Patrycja Bielawiec; Barbara Malinowska; Irena Kasacka; Adrian Chabowski
Journal:  Molecules       Date:  2020-04-21       Impact factor: 4.411

Review 3.  Cannabinoids in arterial, pulmonary and portal hypertension - mechanisms of action and potential therapeutic significance.

Authors:  Barbara Malinowska; Marek Toczek; Anna Pędzińska-Betiuk; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2018-04-14       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.